Exclusive Summary

• - Large T2D population plus strong WHO/ADA guideline endorsement for SGLT2 with metformin makes FDC demand resilient and fast-growing.
• - Entering the global patent/exclusivity tail window (≈2025–2029) enables multi-country generic access and distributor-led launches.
• - The 5mg/500mg strength facilitates initiation and BID titration, improving tolerability and fitting broad inpatient and retail substitution.
• - With solid quality/BE and reliable supply, a sharp price advantage versus originator can win tenders and private channel uptake quickly.
• - ICH-aligned development and major certifications (EU GMP/US FDA/WHO-PQ) plus full stability/BE packages materially raise registration and tender success.